OOIR: Observatory of International Research

Papers

(The TQCC of Statistical Methods in Medical Research is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Covariate adjustment in Bayesian adaptive randomized controlled trials	181
Time-varying coefficient additive hazards model with latent variables	111
Interval estimation in three-class receiver operating characteristic analysis: A fairly general approach based on the empirical likelihood	41
Exact interval estimation for the linear combination of binomial proportions	33
Omnibus test for restricted mean survival time based on influence function	33
Confidence estimation based on data from independent studies	31
Equivalence tests for ratio of means in bioequivalence studies under crossover design	28
Implementing response-adaptive designs when responses are missing: Impute or ignore?	27
Semiparametric copula method for semi-competing risks data subject to interval censoring and left truncation: Application to disability in elderly	21
A Bayesian beta-binomial piecewise growth mixture model for longitudinal overdispersed binomial data	21
Analysis of hospital readmissions with competing risks	20
A new cure model accounting for longitudinal data and flexible patterns of hazard ratios over time	20
Joint meta-analysis of two diagnostic tests accounting for within and between studies dependence	20
Accounting for informative observation process in transition models of binary longitudinal outcome: Application to medical record data	18
Modeling and estimating a threshold effect: An application to improving cardiac surgery practices	18
Generalised pairwise comparisons for trend: An extension to the win ratio and win odds for dose-response and prognostic variable analysis with arbitrary statements of outcome preference	18
Investigations of sharp bounds for causal effects under selection bias	18
A capture-recapture modeling framework emphasizing expert opinion in disease surveillance	17
Using shrinkage methods to estimate treatment effects in overlapping subgroups in randomized clinical trials with a time-to-event endpoint	16
On flexible inverse probability of treatment and intensity weighting: Informative censoring, variable selection, and weight trimming	16
Multiplicative versus additive modelling of causal effects using instrumental variables for survival outcomes – a comparison	15
Response-adaptive treatment randomization for multiple comparisons of treatments with recurrent event responses	15
Analyzing heterogeneity in biomarker discriminative performance through partial time-dependent receiver operating characteristic curve modeling	13
Random survival forests with multivariate longitudinal endogenous covariates	13
New clinical trial design borrowing information across patient subgroups based on fusion-penalized regression models	13

Correlational analyses of biomarkers that are harmonized through a bridging study due to measurement errors	12
Nonparametric analysis of doubly truncated and interval-censored data	12
Challenges of modelling approaches for network meta-analysis of time-to-event outcomes in the presence of non-proportional hazards to aid decision making: Application to a melanoma network	12
A family of Bayesian prognostic and predictive covariate-adjusted response-adaptive randomization designs	12
An iterative matrix uncertainty selector for high-dimensional generalized linear models with measurement errors	12
Generalized Bayesian kernel machine regression	12
Bayesian order constrained adaptive design for phase II clinical trials evaluating subgroup-specific treatment effect	12
Competing risks models with two time scales	11
Simultaneous confidence intervals for an extended Koch-Röhmel design in three-arm non-inferiority trials	11
Penalized variable selection in multi-parameter regression survival modeling	11
Covariate selection for optimizing balance with an innovative adaptive randomization approach	11
A unified approach based on multidimensional scaling for calibration estimation in survey sampling with qualitative auxiliary information	10
Evaluating prognostic biomarkers for survival outcomes subject to informative censoring	10
Familywise error rate control for block response-adaptive randomization	10
Fitting joint models of longitudinal observations and time to event by sequential Bayesian updating	10
A simple and robust parametric shared frailty model for recurrent events with the competing risk of death: An application to the Carvedilol Prospective Randomized Cumulative Survival trial	9
Modified Brier score for evaluating prediction accuracy for binary outcomes	9
Quantifying proportion of treatment effect by surrogate endpoint under heterogeneity	9
Allowing for stratification in sample size planning of two-arm trials with continuous or binary outcome: Overview and tutorial	9
A Bayesian genomic selection approach incorporating prior feature ordering and population structures with application to coronary artery disease	9
Quantification of the influence of risk factors with application to cardiovascular diseases in subjects with type 1 diabetes	9
Smoothing Lexis diagrams using kernel functions: A contemporary approach	9
Modeling the patient mix for risk-adjusted CUSUM charts	9
A generalization of moderated statistics to data adaptive semiparametric estimation in high-dimensional biology	8
More efficient estimators of the area under the receiver operating characteristic curve in paired ranked set sampling	8
Complete effect decomposition for an arbitrary number of multiple ordered mediators with time-varying confounders: A method for generalized causal multi-mediation analysis	8
Adjusting for switches to multiple treatments: Should switches be handled separately or combined?	8
Sample size calculation for multi-arm parallel design with restricted mean survival time	8
Causal simulation experiments: Lessons from bias amplification	8
Estimating a time-to-event distribution from right-truncated data in an epidemic: A review of methods	8
The effect of estimating prevalences on the population-wise error rate	8
Model-based adaptive randomization procedures for heteroscedasticity of treatment responses	8
Change plane model averaging for subgroup identification	8
Review of sample size determination methods for the intraclass correlation coefficient in the one-way analysis of variance model	7
Hunting for protective drugs at the break of a pandemic: Causal inference from hospital data	7
Space-time interactions in Bayesian disease mapping with recent tools: Making things easier for practitioners	7
Statistical methods for clinical trials interrupted by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) pandemic: A review	7
A competing risks regression model for the association between time-varying opioid exposure and risk of overdose	7
Using horseshoe prior for incorporating multiple historical control data in randomized controlled trials	7
MISL: Multiple imputation by super learning	7
Estimation and inference on the partial volume under the receiver operating characteristic surface	7
Testing for marginal covariate effect when the subgroup size induced by the covariate is informative	7
The analysis of COVID-19 in-hospital mortality: A competing risk approach or a cure model?	7
Regression analysis of multivariate recurrent event data allowing time-varying dependence with application to stroke registry data	7
CFO: Calibration-free odds design for phase I/II clinical trials	7
A Bayesian latent class approach to causal inference with longitudinal data	6
Improved and computationally stable estimation of relative risk regression with one binary exposure	6
BOIN-ETC: A Bayesian optimal interval design considering efficacy and toxicity to identify the optimal dose combinations	6
A tight fit of the SIR dynamic epidemic model to daily cases of COVID-19 reported during the 2021–2022 Omicron surge in New York City: A novel approach	6
Using short-term endpoints to improve interim decision making and trial duration in two-stage phase II trials with nested binary endpoints	6

Comparison of statistical methods for the analysis of patient-reported outcomes in randomised controlled trials: A simulation study	6
Use of clinical tolerance limits for assessing agreement	6
A Weibull mixture cure frailty model for high-dimensional covariates	6
Mid-quantile regression for discrete responses	6
Estimation in discrete time coarsened multivariate longitudinal models	6
Fixed and random effect selections in generalized linear mixed models	6
Cause-specific hazard Cox models with partly interval censoring – Penalized likelihood estimation using Gaussian quadrature	6
Estimand-based inference in the presence of long-term survivors	6
Interval estimation for the Youden index of a continuous diagnostic test with verification biased data	6
Using circulating tumor DNA as a novel biomarker of efficacy for dose-finding designs in oncology	6
A generalized epidemiological model with dynamic and asymptomatic population	6
Local linear approximation with Laplacian smoothing penalty and application in biology	6
Test sensitivity in a prospective cancer screening program: A critique of a common proxy measure	6
Combining multiple biomarkers linearly to minimize the Euclidean distance of the closest point on the receiver operating characteristic surface to the perfection corner in trichotomous settings	6
qTPI: A quasi-toxicity probability interval design for phase I trials with multiple-grade toxicities	6
On recurrent-event win ratio	6
Using Bayesian evidence synthesis to quantify uncertainty in population trends in smoking behaviour	6
A new framework for semi-Markovian parametric multi-state models with interval censoring	6
Group lasso priors for Bayesian accelerated failure time models with left-truncated and interval-censored data	6
Multiple imputation approaches for epoch-level accelerometer data in trials	6
Time-dependent receiver operating characteristic curve estimator for correlated right-censored time-to-event data	6
Regularization approaches in clinical biostatistics: A review of methods and their applications	5
Additive hazards model with time-varying coefficients and imaging predictors	5
Adaptive enrichment trial designs using joint modelling of longitudinal and time-to-event data	5
Simulation extrapolation method for measurement error: A review	5
Heterogeneous treatment effect estimation for observational data using model-based forests	5
Generalized fiducial inference for the restricted mean survival time	5
Unbiased and robust analysis of co-localization in super-resolution images	5
An objective Bayesian approach to estimation in multistage experiments	5
An overview of optimal designs under a given budget in cluster randomized trials with a binary outcome	5
Comparisons of various estimates of the I2 statistic for quantifying between-study heterogeneity in meta-analysis	5
Unified approach to optimal estimation of mean and standard deviation from sample summaries	5
Average treatment effect on the treated, under lack of positivity	5
Augmented two-stage estimation for treatment switching in oncology trials: Leveraging external data for improved precision	5
Bivariate copula regression models for semi-competing risks	5
Bayesian analysis of joint quantile regression for multi-response longitudinal data with application to primary biliary cirrhosis sequential cohort study	5
Editorial	5
Health utility adjusted survival: A composite endpoint for clinical trial designs	5
Group sequential analysis of marked point processes: Plasma donation trials	5
Factorial survival analysis for treatment effects under dependent censoring	5
Distribution-free control charts for mixed-type data based on rank of interpoint distances	5
LASSO-type instrumental variable selection methods with an application to Mendelian randomization	5
Solutions to problems of nonexistence of parameter estimates and sparse data bias in Poisson regression	5
Variance partitioning in spatio-temporal disease mapping models	5
Sample sizes required to estimate the protective efficacy of a vaccine when there is an unequal allocation of individuals across the vaccine and placebo groups	5
The “Why” behind including “Y” in your imputation model	5
Semiparametric generalized estimating equations for repeated measurements in cross-over designs	5
MEGH: A parametric class of general hazard models for clustered survival data	5
A new measure to quantify sedentary behavior using accelerometer data: Application to the Hispanic Community Health Study/Study of Latinos	5
Divided-and-combined omnibus test for genetic association analysis with high-dimensional data	5
Measuring the individualization potential of treatment individualization rules: Application to rules built with a new parametric interaction model for parallel-group clinical trials	4
Optimising error rates in programmes of pilot and definitive trials using Bayesian statistical decision theory	4
A comparison of various aggregation functions in multi-criteria decision analysis for drug benefit–risk assessment	4
Data-driven clustering of infectious disease incidence into age groups	4
Bivariate joint models for survival and change of cognitive function	4
Methods for comparative effectiveness based on time to confirmed disability progression with irregular observations in multiple sclerosis	4
Clustering functional data using forward search based on functional spatial ranks with medical applications	4
Biomarker-driven optimal designs for patient enrollment restriction	4
Comparison of random forest methods for conditional average treatment effect estimation with a continuous treatment	4
Graphical methods to illustrate the nature of the relation between a continuous variable and the outcome when using restricted cubic splines with a Cox proportional hazards model	4
Efficient estimation of the marginal mean of recurrent events in randomized controlled trials	4
Bayesian variable selection in hierarchical difference-in-differences models	4
Simulating time-to-event data subject to competing risks and clustering: A review and synthesis	4
Efficient algorithms for survival data with multiple outcomes using the frailty model	4
Quantile outcome adaptive lasso: Covariate selection for inverse probability weighting estimator of quantile treatment effects	4
Jointly assessing multiple endpoints in pilot and feasibility studies	4
Estimating dynamic treatment regimes for ordinal outcomes with household interference: Application in household smoking cessation	4
Sample size determination for adaptive crossover trial in detecting gene-drug interactions	4
Strategies to boost statistical efficiency in randomized oncology trials with primary time-to-event endpoints	4
Causal rule ensemble method for estimating heterogeneous treatment effect with consideration of prognostic effects	4
Extended excess hazard models for spatially dependent survival data	4
Covariate-adjusted inference for doubly adaptive biased coin design	4
Using inverse probability of censoring weighting to estimate hypothetical estimands in clinical trials: Should we implement stabilisation, and if so how?	4